CDIO vs. VOR, VTGN, IFRX, IGMS, EXOZ, ADAP, CLSD, CLLS, RANI, and EPIX
Should you be buying Cardio Diagnostics stock or one of its competitors? The main competitors of Cardio Diagnostics include Vor Biopharma (VOR), Vistagen Therapeutics (VTGN), InflaRx (IFRX), IGM Biosciences (IGMS), Exozymes (EXOZ), Adaptimmune Therapeutics (ADAP), Clearside Biomedical (CLSD), Cellectis (CLLS), Rani Therapeutics (RANI), and ESSA Pharma (EPIX). These companies are all part of the "pharmaceutical products" industry.
Cardio Diagnostics vs.
Vor Biopharma (NYSE:VOR) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk, institutional ownership and community ranking.
97.3% of Vor Biopharma shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 4.7% of Vor Biopharma shares are owned by insiders. Comparatively, 22.3% of Cardio Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Vor Biopharma has a beta of -0.21, suggesting that its share price is 121% less volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 3.73, suggesting that its share price is 273% more volatile than the S&P 500.
Vor Biopharma received 52 more outperform votes than Cardio Diagnostics when rated by MarketBeat users. However, 80.00% of users gave Cardio Diagnostics an outperform vote while only 70.89% of users gave Vor Biopharma an outperform vote.
In the previous week, Cardio Diagnostics had 1 more articles in the media than Vor Biopharma. MarketBeat recorded 1 mentions for Cardio Diagnostics and 0 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.00 beat Cardio Diagnostics' score of -1.00 indicating that Vor Biopharma is being referred to more favorably in the media.
Vor Biopharma has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -22,732.03%. Vor Biopharma's return on equity of 0.00% beat Cardio Diagnostics' return on equity.
Vor Biopharma has higher earnings, but lower revenue than Cardio Diagnostics.
Vor Biopharma presently has a consensus price target of $8.86, indicating a potential upside of 1,262.64%. Cardio Diagnostics has a consensus price target of $2.00, indicating a potential upside of 412.95%. Given Vor Biopharma's higher possible upside, analysts clearly believe Vor Biopharma is more favorable than Cardio Diagnostics.
Summary
Vor Biopharma beats Cardio Diagnostics on 8 of the 13 factors compared between the two stocks.
Get Cardio Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardio Diagnostics Competitors List
Related Companies and Tools
This page (NASDAQ:CDIO) was last updated on 4/21/2025 by MarketBeat.com Staff
Buy CDIO Stock Free CDIO Stock Alerts